Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? [Yahoo! Finance]
Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications [Yahoo! Finance]
How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript [Seeking Alpha]